Bayesian Capital Management’s Organogenesis Holdings ORGO Stock Holding History

Bayesian Capital Management’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,900	Closed	-$98.9K	–	784
2025 Q1	$98.9K	Buy	+22,900	New	+$92.5K	0.02%	542
2024 Q3	–	Sell	-10,584	Closed	-$29.6K	–	950
2024 Q2	$29.6K	Buy	10,584 +300	+3%	+$805	﹤0.01%	675
2024 Q1	$29.2K	Sell	10,284 -5,800	-36%	-$19.7K	﹤0.01%	743
2023 Q4	$65.8K	Buy	+16,084	New	+$45K	0.01%	671
2022 Q2	–	Sell	-39,900	Closed	-$304K	–	994
2022 Q1	$304K	Buy	+39,900	New	+$309K	0.05%	515

Other funds holding ORGO

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's ORGO Position: Q2 2025 in Review

Bayesian Capital Management sold out of Organogenesis Holdings (ORGO) in Q2 2025, closing a stake of 22,900 shares — an estimated $98.9K sold.

Bayesian Capital Management first reported a position in ORGO in Q1 2022 and held it in 5 quarters. The position peaked at $304K in Q1 2022. 115 funds tracked by Wall St. Rank hold ORGO as of Q2 2025.

Bayesian Capital Management reported no remaining Organogenesis Holdings position as of Q2 2025 after selling out during the quarter.
Bayesian Capital Management sold 22,900 Organogenesis Holdings shares in Q2 2025, an estimated $98.9K.
Bayesian Capital Management first reported a position in Organogenesis Holdings in Q1 2022 and held it in 5 quarters.
Bayesian Capital Management's Organogenesis Holdings position peaked at $304K in Q1 2022.
115 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.